Transplantation
Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...
Researchers had not previously studied the long-term impact of omidubicel...
New research suggests venetoclax-containing regimens with intensive treatment and may improve outcomes.
Advertisement
First-line treatment with tagraxofusp led to an overall response rate of 75% in patients with blastic plasmacytoid...
Aaron Logan, MD, PhD, and Elias Jabbour, MD, discussed whether MRD negativity indicates a cure in patients with AML.
A triplet treatment plus autologous stem-cell transplantation was associated with longer progression...
Advertisement
Nearly a third of patients with chronic graft-versus-host disease (GVHD) were able to discontinue long-term systemic therapy ...
The European Medicines Agency validated a type II variation for the extension of the indication for lisocabtagene maraleucel ...
Mocravimod is a synthetic, sphingosine 1-phosphate receptor modulator that has been assessed in phase I and II trials.
Mocravimod is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator.
There was a global increase of 6.2% in autologous HSCT and 7.0% in allogeneic HSCT.
Researchers retrospectively analyzed 580 patients with AML receiving HSCT between January 1999 and November 2020.
Long-term lymphoma survivors who underwent transplant had impaired health-related quality of life.
Drs. Short and Webster, discussed their differing views of the current position of transplantation in the treatment of ALL.
Abatacept has been U.S. Food and Drug Administraion (FDA)-approved as acute graft-versus-host disease (aGVHD) prophylaxis for ...
Life expectancy has improved since 1974 but remains 20.8% lower compared with the general population.
A study found that for people with MCL, patient demographics were associated with likelihood of receiving ASHCT.
Return to work is a marker of functional recovery in patients with cancer.
Most guidelines recommend induction therapy followed by autologous HCT.
Clinical guidelines recommend upfront AHCT for eligible patients with MM.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.